AbbVie's Upadacitinib Meets Primary Endpoint in Phase IIb

Credit: Shutterstock photo

AbbVie 's ABBV shares have increased more than 6% after the company announced that its oral JAK-1 selective inhibitor, upadacitinib (ABT-494), met primary endpoints in a phase IIb study for treatment of adult patients with atopic dermatitis, also known as eczema. The company plans to advance the candidate into phase III studies next year.

AbbVie's shares have outperformed the industry year to date. The stock has surged 30.6% compared with the industry's 14.5% rally during the period.

The study's primary outcome was the mean percentage change in Eczema Area and Severity Index (EASI) score, a tool used to measure the extent of disease severity. In the trial, upadacitinibshowed greater mean percentage change from baseline in EASI score compared with placebo at 16 weeks. Also, 50% of patients receiving 30 mg once-daily dose of upadacitinib showed almost clear skin. Additionally, the study met secondary endpoints, demonstrating a significant reduction in skin-itching.

Upadacitinib is also being investigated in six phase III studies for rheumatoid arthritis. Other researches are also underway for treatment of Crohn's disease, ulcerative colitis and psoriatic arthritis.

Per National Eczema Association, around 31.6 million people in the United States have some form of atopic dermatitis. Of them, 4.1 million children are affected by the disease. Hence, approval of the drug will provide the company with access to a huge patient population suffering from the disease in the United States.

Notably in March, Regeneron Pharmaceuticals, Inc. REGN along with partner Sanofi SNY had launched Dupixent (dupilumab) Injection for treating atopic dermatitis. Thus, upadacitinib awaits a combat against competitive pressure in the market, once approved.

AbbVie Inc. Price

AbbVie Inc. Price | AbbVie Inc. Quote

Zacks Rank & Stocks to Consider

AbbVie currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the pharma sector is Aduro Biotech, Inc. ADRO , carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

Aduro Biotech's loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.26 to $1.24 for 2018 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Sanofi (SNY): Free Stock Analysis Report

AbbVie Inc. (ABBV): Free Stock Analysis Report

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More